You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Baxter
Boehringer Ingelheim
Medtronic
Merck
McKinsey
Harvard Business School

Last Updated: December 5, 2020

DrugPatentWatch Database Preview

Patent: 8,609,089

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,609,089
Title:Compositions of PD-1 antagonists and methods of use
Abstract: Methods of treating cancer and infectious diseases utilizing a treatment regimen comprising administering a compound that reduces inhibitory signal transduction in T cells, in combination with a potentiating agent, such as cyclophosphamide, to produce potent T cell mediated responses, are described. Compositions comprising the PD-1 antagonists and potentiating agents useful in the methods of the invention are also disclosed.
Inventor(s): Langermann; Solomon (Baltimore, MD), Liu; Linda (Clarksville, MD)
Assignee: Amplimmune, Inc. (Gaithersburg, MD)
Application Number:13/332,154
Patent Claims:see list of patent claims

Details for Patent 8,609,089

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial Amplimmune, Inc. (Gaithersburg, MD) 2028-08-25 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial Amplimmune, Inc. (Gaithersburg, MD) 2028-08-25 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 8,609,089

Country Patent Number Estimated Expiration
South Africa 201101119   Start Trial
South Africa 201101120   Start Trial
South Africa 201107552   Start Trial
World Intellectual Property Organization (WIPO) 2010027423   Start Trial
World Intellectual Property Organization (WIPO) 2010027827   Start Trial
World Intellectual Property Organization (WIPO) 2010027828   Start Trial
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
Express Scripts
AstraZeneca
Merck
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.